The Inotrope Evaluation and Research Patient Registry
Purpose
The INTERPRET Inotrope Evaluation and Research Patient Registry is a longitudinal, observational study designed to look at the demographics and outcomes of heart failure patients on inotropic therapy administered in the home or infusion suite setting. The data gathered in this registry will provide information on how a patient's quality of life and symptoms change over time while on inotrope therapy, and help healthcare providers to have a better understanding of the benefits and risks associated with bridge-to-treatment and palliative care.
Condition
- Heart Failure
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Patient must be prescribed inotropic treatment (milrinone, dobutamine or dopamine) - Patient must be referred to Coram for this treatment in an alternate site of care, either home or infusion suite - Patient must be willing to receive care and comply with the teaching and training necessary to administer treatment - Patient is age 18 or over
Exclusion Criteria
- Patient is unable to start, or stops taking, inotropic medication - Patient and/or patient insurance will not cover cost of home inotropic treatment with Coram, or patient elects not to start treatment - Patient is under the age of 18
Study Design
- Phase
- Study Type
- Observational [Patient Registry]
- Observational Model
- Cohort
- Time Perspective
- Prospective
More Details
- Status
- Completed
- Sponsor
- Coram Clinical Trials
Study Contact
Detailed Description
Eligible patients will be consented by the site investigator or staff to participate in the Registry at the time of referral for home care. Clinical data, including dosing, symptom severity, lab values, and hospitalizations, along with data on quality-of-life and patient compliance with treatment, will be collected by the home care nurses and pharmacists. The Registry's goal is to significantly contribute to the medical understandings of heart failure treatment and to improve the quality of care for heart failure patients in the United States through active publication of registry findings and disease management approaches.